title: The modified selenenyl amide, M-hydroxy ebselen, attenuates diabetic nephropathy and diabetes-associated atherosclerosis in ApoE/GPx1 double knockout mice.
abstract: Seleno-organic glutathione peroxidase (GPx) mimetics, including ebselen (Eb), have been tested in in vitro studies for their ability to scavenge reactive oxygen and nitrogen species, including hydrogen peroxide and peroxynitrite. In this study, we investigated the efficacies of two Eb analogues, m-hydroxy ebselen (ME) and ethanol-ebselen (EtE) and compared these with Eb in cell based assays. We found that ME is superior in attenuating the activation of hydrogen peroxide-induced pro-inflammatory mediators, ERK and P38 in human aortic endothelial cells. Consequently, we investigated the effects of ME in an in vivo model of diabetes, the ApoE/GPx1 double knockout (dKO) mouse. We found that ME attenuates plaque formation in the aorta and lesion deposition within the aortic sinus of diabetic dKO mice. Oxidative stress as assessed by 8-OHdG in urine and nitrotyrosine immunostaining in the aortic sinus and kidney tubules, was reduced by ME in diabetic dKO mice. ME also attenuated diabetes-associated renal injury which included tubulointerstitial fibrosis and glomerulosclerosis. Furthermore, the bioactivity of the pro-fibrotic cytokine transforming growth factor-β (TGF-β) as assessed by phospho-Smad2/3 immunostaining was attenuated after treatment with ME. TGF-β-stimulated increases in collagen I and IV gene expression and protein levels were attenuated by ME in rat kidney tubular cells. However, in contrast to the superior activity of ME in in vitro and cell based assays, ME did not further augment the attenuation of diabetes-associated atherosclerosis and renal injury in our in vivo model when compared with Eb. In conclusion, this study strengthens the notion that bolstering GPx-like activity using synthetic mimetics may be a useful therapeutic strategy in lessening the burden of diabetic complications. However, these studies highlight the importance of in vivo analyses to test the efficacies of novel Eb analogues, as in vitro and cell based assays are only partly predictive of the in vivo situation.
authors.affiliation: Oxidative Stress Group, Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
authors.forename: Sih Min
authors.initials: SM
authors.lastname: Tan
authors.forename: Arpeeta
authors.initials: A
authors.lastname: Sharma
authors.forename: Derek Y C
authors.initials: DY
authors.lastname: Yuen
authors.forename: Nada
authors.initials: N
authors.lastname: Stefanovic
authors.forename: Guy
authors.initials: G
authors.lastname: Krippner
authors.forename: Govindasamy
authors.initials: G
authors.lastname: Mugesh
authors.forename: Zhonglin
authors.initials: Z
authors.lastname: Chai
authors.forename: Judy B
authors.initials: JB
authors.lastname: de Haan
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency* / Q000235:genetics; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism; D001393:Azoles / Q000737:chemistry / Q000627:therapeutic use*; D002460:Cell Line; D003921:Diabetes Mellitus, Experimental; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000172:deficiency* / Q000235:genetics; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use; D054833:Isoindoles; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008956:Models, Chemical; D016566:Organoselenium Compounds / Q000737:chemistry / Q000627:therapeutic use*; D051381:Rats
chemical_list: D001057:Apolipoproteins E; D001393:Azoles; D007004:Hypoglycemic Agents; D054833:Isoindoles; D016566:Organoselenium Compounds; C042986:ebselen; D005979:Glutathione Peroxidase